title: Value of Genetic Testing for Hereditary Colorectal Cancer in a Probability-Based US Online Sample.
abstract: . While choices about genetic testing are increasingly common for patients and families, and public opinion surveys suggest public interest in genomics, it is not known how adults from the general population value genetic testing for heritable conditions. We sought to understand in a US sample the relative value of the characteristics of genetic tests to identify risk of hereditary colorectal cancer, among the first genomic applications with evidence to support its translation to clinical settings.
  
  
  
  . A Web-enabled choice-format conjoint survey was conducted with adults age 50 years and older from a probability-based US panel. Participants were asked to make a series of choices between 2 hypothetical blood tests that differed in risk of false-negative test, privacy, and cost. Random parameters logit models were used to estimate preferences, the dollar value of genetic information, and intent to have genetic testing.
  
  
  
  . A total of 355 individuals completed choice-format questions. Cost and privacy were more highly valued than reducing the chance of a false-negative result. Most (97% [95% confidence interval (CI)], 95%-99%) would have genetic testing to reduce the risk of dying of colorectal cancer in the best scenario (no false negatives, results disclosed to primary care physician). Only 41% (95% CI, 25%-57%) would have genetic testing in the worst case (20% false negatives, results disclosed to insurance company).
  
  
  
  . Given the characteristics and levels included in the choice, if false-negative test results are unlikely and results are shared with a primary care physician, the majority would have genetic testing. As genomic services become widely available, primary care professionals will need to be increasingly knowledgeable about genetic testing decisions.
authors.affiliation: Health Services Research and Development Program, Birmingham Veterans Affairs Medical Center, Birmingham, Alabama, USA (SJK)|Division of Preventive Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA (SJK)
authors.forename: Sara J
authors.initials: SJ
authors.lastname: Knight
authors.affiliation: CHEOR, Specialty Medicine, Bayer Healthcare Pharmaceuticals, Inc., Whippany, New Jersey, USA (AFM)
authors.forename: Ateesha F
authors.initials: AF
authors.lastname: Mohamed
authors.affiliation: Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada (DAM)
authors.forename: Deborah A
authors.initials: DA
authors.lastname: Marshall
authors.affiliation: Department of Medicine, Stanford University, Palo Alto, California, USA (UL)
authors.forename: Uri
authors.initials: U
authors.lastname: Ladabaum
authors.affiliation: Department of Clinical Pharmacy and Institute for Health Policy Studies, University of California at San Francisco, San Francisco, California, USA (KAP)
authors.forename: Kathryn A
authors.initials: KA
authors.lastname: Phillips
authors.affiliation: Departments of Medicine and Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, California, USA (JMEW)
authors.forename: Judith M E
authors.initials: JM
authors.lastname: Walsh
keywords: discrete choice; genetics; internal medicine; oncology; utility assessment